Table 3

Molecular response to IFN or IM treatment and probability of TFR 3 years after stopping IM

Proportion of patients in TFR
MedianRange<Median>MedianP
IFN-IM cohort      
 BCR-ABL% at IM start (n = 16) 0.76 0-86 0.600 0.500 .48 
 Days to MR4.0 (n = 18) 258 78-1199 0.667 0.444 .27 
 Days to first UMRD (n = 17) 244 89-1841 0.750 0.333 .04 
IM-only cohort      
 Days to MMR (n = 16) 177 80-495 0.469 0.375 .46 
 Days to MR4.0 (n = 17) 427 160-1209 0.375 0.444 .95 
 Days to first UMRD (n = 17) 475 160-1608 0.429 0.400 .53 
Proportion of patients in TFR
MedianRange<Median>MedianP
IFN-IM cohort      
 BCR-ABL% at IM start (n = 16) 0.76 0-86 0.600 0.500 .48 
 Days to MR4.0 (n = 18) 258 78-1199 0.667 0.444 .27 
 Days to first UMRD (n = 17) 244 89-1841 0.750 0.333 .04 
IM-only cohort      
 Days to MMR (n = 16) 177 80-495 0.469 0.375 .46 
 Days to MR4.0 (n = 17) 427 160-1209 0.375 0.444 .95 
 Days to first UMRD (n = 17) 475 160-1608 0.429 0.400 .53 
View Large